AR061270A1 - Derivados de benzamida y usos relacionados de los mismos - Google Patents

Derivados de benzamida y usos relacionados de los mismos

Info

Publication number
AR061270A1
AR061270A1 ARP070102479A ARP070102479A AR061270A1 AR 061270 A1 AR061270 A1 AR 061270A1 AR P070102479 A ARP070102479 A AR P070102479A AR P070102479 A ARP070102479 A AR P070102479A AR 061270 A1 AR061270 A1 AR 061270A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
so2r
haloalkyl
cycloalkyl
Prior art date
Application number
ARP070102479A
Other languages
English (en)
Inventor
Dustin Mcminn
Yosup Rew
Daqing Sun
Zhulun Wang
Jay P Powers
Michael Degraffenreid
David Jonathan Julian
Jacob Kaizerman
Xuelei Yan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38814464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR061270A1 publication Critical patent/AR061270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Abstract

Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), o sus sales aceptables para uso farmacéutico, solvatos, estereoisomeros o prodrogas, en donde: n es 0, 1, o 2; R1 es un miembro seleccionado entre el grupo que consiste de -OH, halogeno y haloalquilo C1-8; R2 y R3 son miembros seleccionados en forma independiente entre el grupo que consiste de halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-8, haloalquilo C1-8, hidroxialquilo C2-8 y cicloalquilo C3-8, en donde no más de dos de R1, R2 y R3 son halogeno; R4 es un miembro seleccionado entre el grupo que consiste de hidrogeno, halogeno, alquilo C1-8 y cicloalquilo C3-8; R5 se selecciona entre el grupo que consiste de alquilo C1-8, haloalquilo C1-8, hidroxialquilo C2-8, cicloalquilo C3-8, y heterocicloalquilo C3-8; R6 se selecciona entre el grupo que consiste de alquilo C1-8, alquenilo C2-8, haloalquilo C1-8, aril(C1-6)alquilo, cicloalquilo C3-8, heterocicloalquilo C3-8, heteroarilo, y arilo; en donde el grupo arilo y heteroarilo está opcionalmente sustituido por sustituyentes cuyo numero va de uno al numero de valencias abiertas del grupo arilo o heteroarilo seleccionados entre el grupo que consiste de -halo, -OR', -OC(O)R', - NR'Rö, -SR', -R', -CN, -NO2, -CO2R', -C(O)NR'Rö, -C(O)R', -OC(O)NR'Rö, -NRöC(O)R', -NRöCO2R', -NRö'C(O)NR'Rö, -NR'öSO2NR'Rö, -NHC(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', -SO2R', -SO2NR'Rö, -NRöSO2R', -N3, -CH(Ph)2, perfluoroalcoxi y perfluoro(C1-4)alquilo; en donde R5 o R6 está opcionalmente sustituido con entre uno y dos miembros seleccionados entre el grupo que consiste de halogeno, -CN, -NO2, alquilo C1-4, alquenilo C2-8, alquinilo C2-8, alcoxi C1-4, haloalquilo C1-4, hidroxialquilo C2-4, -C(O)R', -C(O)OR', -NR'C(O)OR', -OR', -SR', -OC(O)R', -C(O)N(R')2, -S(O)R', -SO2R', -SO2N(R')2, -N(R')2, -NR'C(O)R' y -NR'SO2R'; R7 se selecciona entre el grupo que consiste de halogeno, -CN, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, haloalquilo C1-8, hidroxialquilo C1-8, -C(O)R', -C(O)OR', -NR'C(O)OR', -OR', -OC(O)R', -C(O)N(R')2, -S(O)R', -SO2R', -SO2N(R')2, -N(R')2, -NR'C(O)R', - NR'SO2R', -X-CN, -X-C(O)R', -X-C(O)OR', -X-NR'C(O)OR', -X-OR', -X-OC(O)R', -X- C(O)N(R')2, -X-S(O)R', -X-SO2R', -X-SO2N(R')2, -X-N(R')2, -X-NR'C(O)R', en donde cada alquilo, alquenilo, y alquinilo se puede sustituir por uno a tres sustituyentes seleccionados entre el grupo que consiste de -OR', =O, =NR', =N-OR', -NR'Rö, -SR', - halo, -SiR'RöR'ö, -OC(O)R', -C(O)R', -CO2R', -CONR'Rö, OC(O)NR'Rö, -NRöC(O)R', -NR'öC(O)NR'Rö, -NR'öSO2NR'Rö, -NRöCO2R', -NHC(NH2)=NH, -NR'C(NH2)=NH, - NHC(NH2)=NR', -S(O)R', -SO2R', -SO2NR'Rö, -NRöSO2R', -CN y -NO2; R6 y R7 se pueden combinar para formar un cicloalquilo C3-8 o heterocicloalquilo C3-8; R8 se selecciona entre el grupo que consiste de halogeno, -CN, alquilo C1-6, alquiloxi C1-6, y -OH; X es un grupo alquileno C1-8 de cadena lineal o ramificada; cada instancia de R', Rö, y R'ö es en forma independiente hidrogeno o un miembro no sustituido seleccionado entre el grupo que consiste de alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-4-alquilo C1-4, haloalquilo C1-8, hidroxialquilo C2-8, cicloalquilo C3-8, heterocicloalquilo C3-8, heteroarilo, arilo, cicloaIquil C3-8-aIquilo C1-6, heterocicloalquil C3-8-alquilo C1-6, heteroaril(C1-6)alquilo, aril(C1-6)alquilo, o dos R' grupos, cuando están unidos al mismo átomo de nitrogeno, se pueden combinar con el átomo de nitrogeno al cual están unidos para formar un grupo heterociclo o heteroarilo; y con la condicion de que cuando R1 es -OH, luego R2 y R3 no son los dos CF3.
ARP070102479A 2006-06-08 2007-06-07 Derivados de benzamida y usos relacionados de los mismos AR061270A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81175806P 2006-06-08 2006-06-08
US87953907P 2007-01-10 2007-01-10

Publications (1)

Publication Number Publication Date
AR061270A1 true AR061270A1 (es) 2008-08-13

Family

ID=38814464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102479A AR061270A1 (es) 2006-06-08 2007-06-07 Derivados de benzamida y usos relacionados de los mismos

Country Status (9)

Country Link
US (1) US8772296B2 (es)
EP (1) EP2044004B1 (es)
AR (1) AR061270A1 (es)
AU (1) AU2007259144B2 (es)
CA (1) CA2655146C (es)
ES (1) ES2390573T3 (es)
PE (1) PE20080154A1 (es)
TW (1) TW200808695A (es)
WO (1) WO2007145835A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007343726A1 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
MX2009007416A (es) 2007-01-10 2009-07-17 Hoffmann La Roche Derivados de sulfonamida como inhibidores de quimasa.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011336700B2 (en) 2010-12-01 2016-12-22 Janssen Pharmaceutica Nv 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT2772484T (lt) 2011-10-18 2017-12-27 Astellas Pharma Inc. Biciklinis heterociklinis junginys
US8829225B2 (en) * 2012-01-28 2014-09-09 Optmed, Inc. Purification of 1,1-disubstituted ethylene
CN106467477A (zh) * 2016-08-26 2017-03-01 天津雅奥科技发展有限公司 一种合成化合物（1‑环丙基‑1‑氰基‑4‑环己酮）的新方法
CN117800895A (zh) * 2022-09-30 2024-04-02 苏州阿尔脉生物科技有限公司 草酸胺类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465539A (en) * 1891-12-22 Bed-spring
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3918899A (en) * 1974-08-16 1975-11-11 Us Agriculture Carboxymethyl (CM) cottons prepared in non-aqueous media
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4179501A (en) * 1976-11-12 1979-12-18 The Upjohn Company Analgesic N-(2-aminocycloaliphatic)azidobenzamides
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
US4192885A (en) * 1976-11-12 1980-03-11 The Upjohn Company Analgesic N-{2-[N'-(2-furylmethyl and 2-thienyl-methyl)-N'-alkylamino]cycloaliphatic}cyanobenzamides
US4098904A (en) * 1976-11-12 1978-07-04 The Upjohn Company Analgesic n-(2-aminocycloaliphatic)benzamides
US4197308A (en) * 1976-11-12 1980-04-08 The Upjohn Company Analgesic N-(2-heterocyclic-amino cycloaliphatic) benzamides
AU531759B2 (en) * 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4914108A (en) * 1988-03-14 1990-04-03 G. D. Searle & Co. 5-substituted(4,5-c)imidazopyridine compounds which have useful platelet activating factor antagonistic activity
US5019581A (en) * 1988-03-14 1991-05-28 G. D. Searle & Co. 5-substituted (4,5-c) imidazopyridine compounds which have useful platelet activating factor antagonistic activity
US5302601A (en) * 1988-03-14 1994-04-12 G. D. Searle & Co. 5-substituted imidazo[4,5-c]pyridines
US5227384A (en) * 1988-03-14 1993-07-13 G. D. Searle & Co. 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5223539A (en) * 1991-11-22 1993-06-29 G. D. Searle & Co. N,n-di-alkyl(phenoxy)benzamide derivatives
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4239151A1 (de) * 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
US5359073A (en) * 1992-11-24 1994-10-25 G. D. Searle & Co. Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5262426A (en) * 1993-01-22 1993-11-16 G. D. Searle & Co. N,N'-cycloalkyl/alkyl carboxamide 4H-imidazo-[4,5-b]pyridine compounds as PAF antagonists
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5360907A (en) * 1993-06-14 1994-11-01 G.D. Searle & Co. Pyrrolo[3,2-B]pyridinylalkyl benzamide derivatives
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69605025T2 (de) * 1995-03-14 2000-07-20 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
WO1996028205A1 (en) * 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
US5861403A (en) * 1995-10-05 1999-01-19 G. D. Searle & Co. Purinylalkyl benzamide derivatives
US5652363A (en) * 1995-10-05 1997-07-29 C.D. Searle & Co. Pyrido-1,4-oxazinylalkyl-benzamide derivatives
US6251941B1 (en) 1996-04-19 2001-06-26 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
EE03829B1 (et) * 1996-11-11 2002-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Bensonaftüridiinid, nende kasutamine bronhiaalravimi valmistamiseks ning neid sisaldav ravim
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
SK13632000A3 (sk) 1998-03-16 2001-03-12 Inhale Therapeutic Systems, Inc. Spôsob podávania aktívnej látky do pľúc ľudského pacienta a zariadenie na jeho vykonávanie
CA2418744C (en) * 2000-08-16 2010-04-20 F. Hoffmann-La Roche Ag Novel aminocyclohexane derivatives
DE60219595T2 (de) 2001-01-26 2008-01-10 Chugai Seiyaku K.K. Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
US6831193B2 (en) * 2001-05-18 2004-12-14 Abbott Laboratories Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
JP2005533858A (ja) 2002-07-27 2005-11-10 アストラゼネカ アクチボラグ 化合物
WO2004033427A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
WO2004072034A1 (en) 2003-02-17 2004-08-26 F. Hoffmann-La Roche Ag Piperidine-benzenesulfonamide derivatives
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
GB0314054D0 (en) 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
AU2005267289A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US7605289B2 (en) * 2005-06-17 2009-10-20 Amgen, Inc. Benzamide derivatives and uses related thereto

Also Published As

Publication number Publication date
US20070299080A1 (en) 2007-12-27
ES2390573T3 (es) 2012-11-14
TW200808695A (en) 2008-02-16
AU2007259144A1 (en) 2007-12-21
EP2044004A2 (en) 2009-04-08
AU2007259144B2 (en) 2012-04-19
WO2007145835A3 (en) 2008-03-06
CA2655146C (en) 2013-09-24
US8772296B2 (en) 2014-07-08
CA2655146A1 (en) 2007-12-21
PE20080154A1 (es) 2008-04-16
EP2044004B1 (en) 2012-08-15
WO2007145835A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
AR061270A1 (es) Derivados de benzamida y usos relacionados de los mismos
AR059942A1 (es) Derivados de benzamidina y usos relacionados de los mismos
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
AR082768A1 (es) Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR078320A1 (es) Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
AR075475A1 (es) Derivados heterociclicos de piperazina utiles como agentes herbicidas y proceso para combatir el crecimiento de plantas indeseadas.
AR046118A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
HRP20170104T1 (hr) Derivati tipa azaindazola ili diazaindazola za liječenje boli
UY30857A1 (es) Nuevos derivados de n,n'-2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
AR091498A1 (es) DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA
AR083200A1 (es) Compuestos de n-heteroarilo
ES2688575T3 (es) Compuestos heterocíclicos y sus usos
AR057082A1 (es) Derivados de ciclohexilaminisoquinolona
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR047165A1 (es) Derivados de piperazin sulfonilo y composiciones farmaceuticas
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR083167A1 (es) Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas
AR073431A1 (es) Derivados de azacarbolinas 9h- pirrolo (2,3-b:5,4-c) dipiridina , su preparacion y si utilizacion terapeutica
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU23706B7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PA8768301A1 (es) Nuevos derivados tricíclicos, su procedimiento de preparación y las composiciones farmacéuticas que lo contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure